Intervention

Ralinepag

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 4 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials4

Recruiting0

Common conditions11

Lead sponsors shown1

Clinical trials

4 shown

Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsNCT04084678 · 2021-01-20

TERMINATED

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionNCT03683186 · 2019-09-23

ENROLLING_BY_INVITATION

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsNCT03626688 · 2019-01-24

COMPLETED

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial HypertensionNCT02279745 · 2015-07-08

COMPLETED

Common conditions

Pulmonary Arterial Hypertension4 Pulmonary Hypertension3 Cardiovascular Diseases2 Connective Tissue Diseases2 Familial Primary Pulmonary Hypertension2 Hypertension2 Hypertension, Pulmonary2 Lung Diseases2 PAH2 Respiratory Tract Disease2 Vascular Diseases2

Leading sponsors

United Therapeutics 4

Trial status mix

COMPLETED2

ENROLLING_BY_INVITATION1

TERMINATED1

Phase mix

PHASE33

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.